Non-erythropoietic EPO analogue that activates innate repair receptors and reduces neuropathic pain.
Binds to the innate repair receptor (IRR) — a heterodimer of EPO receptor and CD131. Activates tissue protection pathways without stimulating red blood cell production. Reduces neuroinflammation and promotes nerve regeneration.
Designed to separate the tissue-protective effects of EPO from its erythropoietic (red blood cell stimulating) effects. This makes it suitable for research in non-anemic subjects without hematological concerns.
Phase 2 trials showed significant reduction in neuropathic pain in sarcoidosis patients. The unique innate repair receptor mechanism makes ARA-290 distinct from most other peptides in the catalog.